Blood pressure and heart history come first
In the label checked on November 3, 2026, Vyleesi (bremelanotide) is ruled out if high blood pressure is not controlled. It is also ruled out for known disease of the heart or blood vessels.
The label also advises against use when heart or blood-vessel risk is high. This applies even without a known diagnosis of disease.
The label calls this cardiovascular risk: risk involving the heart and blood vessels.
The medicine can briefly raise blood pressure and slow the heartbeat. In human studies, the label says values usually returned to their starting level within 12 hours.
Usually is not a personal guarantee, and a later return does not cancel the conditions in which the label rules out use.
Nausea deserves a direct discussion
In the main Vyleesi trials, nausea occurred in 40.0% of the medicine group and 1.3% of the placebo group.
A placebo is a dummy injection used for comparison; these trials involved women before menopause with HSDD, or distressing low desire.
Vyleesi: 40.0%.
Dummy injection: 1.3%.
Side effects led 18% of the medicine group to leave the trials, compared with 2% of the placebo group.
Those trials also recorded flushing, meaning skin that feels warm and turns red, along with headache and irritation where the injection was given.
These group results do not predict an individual reaction, and they are not rates for an unidentified or compounded preparation.
Ask what a plan for persistent or severe nausea would involve and how to reach the clinical team handling the prescription. Keep that question with the follow-up plan rather than assuming a common effect must be easy to manage.
Skin changes and other medicines
Dark patches on the face, gums or breasts can occur with Vyleesi, and the label did not confirm that every case resolved after stopping.
Bremelanotide can make the stomach empty more slowly. That can slow or reduce how much of a medicine taken by mouth gets into the body, which may delay or weaken its effect.
The label says to avoid combining Vyleesi with oral naltrexone used for alcohol or opioid addiction because the naltrexone treatment could fail.
That interaction statement concerns naltrexone taken by mouth. It is not a direction to stop or adjust another medicine on your own.
The label calls for extra care with severe kidney or liver problems. It has not been tested in people with severe loss of liver function.
Ask the prescriber to review the full medicine and supplement list. If the list changes later, ask how that change will be reviewed too.
Pregnancy, breastfeeding and urgent help
The label does not recommend Vyleesi during pregnancy. Reports in people are too few to establish safety. Animal studies found harm to developing offspring.
In a study of 10 breastfeeding women, very little bremelanotide passed into breast milk after one injection, according to the FDA prescribing information revised in October 2026.
It did not test effects on babies. It did not establish effects on the milk supply. The findings do not prove safety with repeated use.
Bring plans for pregnancy and breastfeeding into a personal care discussion. The newer milk findings matter; an older copy of the label may leave them out.
Emergency help through 911 is called for with severe allergy symptoms such as facial or tongue swelling or difficulty breathing.
That is general emergency information, not a prediction about a particular medicine or a way to diagnose the cause.